Phase 3 ALKS 2680 Narcolepsy Type 1 Study (NCT07540897)

A Phase 3 clinical trial (NCT07540897) for ALKS 2680, an investigational treatment for Narcolepsy Type 1, has been registered on ClinicalTrials.gov. The Brilliance NT1-304 study is enrolling adults and will compare two active dose levels against placebo, with co-primary endpoints of daytime sleepiness and cataplexy reduction. This is an informational study listing; it does not impose any regulatory obligations or compliance requirements on sponsors, investigators, or healthcare providers.

For pharmaceutical sponsors and clinical investigators, this registration signals active Phase 3 development of ALKS 2680 for NT1 and may inform competitive landscape awareness, clinical trial feasibility assessments, and patient referral pathways. No filing, reporting, or compliance action is required in response to this notice.